The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Mapi - Pharma's quick ratio for the quarter that ended in Jun. 2015 was 6.02.
Mapi - Pharma has a quick ratio of 6.02. It generally indicates good short-term financial strength.
The historical rank and industry rank for Mapi - Pharma's Quick Ratio or its related term are showing as below:
MAPI's Quick Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.32 * Ranked among companies with meaningful Quick Ratio only.
Mapi - Pharma Quick Ratio Historical Data
The historical data trend for Mapi - Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Mapi - Pharma Quick Ratio Chart
Mapi - Pharma Annual Data
Trend
Dec12
Dec13
Dec14
Quick Ratio
3.16
1.67
0.79
Mapi - Pharma Semi-Annual Data
Dec12
Dec13
Jun14
Dec14
Jun15
Quick Ratio
3.16
1.67
-
0.79
6.02
Competitive Comparison of Mapi - Pharma's Quick Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mapi - Pharma's Quick Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Mapi - Pharma's Quick Ratio falls into.
Mapi - Pharma Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Mapi - Pharma's Quick Ratio for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mapi - Pharma (NAS:MAPI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Mapi - Pharma Quick Ratio Related Terms
Thank you for viewing the detailed overview of Mapi - Pharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Mapi - Pharma (Mapi - Pharma) Business Description
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MAPI has been successfully added to your